Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | (c) Director and Officer Trading Arrangements
During the three months ended March 31, 2026, Thomas Sciascia, the Company's Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement for the sale of the Company's common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. This plan was adopted on January 21, 2026 and has an expiration date of December 31, 2026. Pursuant to the plan, the aggregate number of options to be exercised, and the aggregate number of shares of common stock to be exercise of those options, is not to exceed 3,947.
None of our other directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the three months ended March 31, 2026. |
| Thomas Sciascia [Member] | |
| Trading Arrangements, by Individual | |
| Name | Thomas Sciascia |
| Title | Chief Scientific Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | January 21, 2026 |
| Expiration Date | December 31, 2026 |
| Arrangement Duration | 345 days |
| Aggregate Available | 3,947 |
| Other Directors or Officers [Member] | |
| Trading Arrangements, by Individual | |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |